drugs glp-1 What to Make of the Coverage and Cost Landscape Costly GLP-1 Drugs are Rarely
Description
In Eli Lilly's pivotal Phase 3 ATTAIN clinical trialsthe studies that led to FDA approvalparticipants taking orforglipron achieved average body weight reductions of approximately 7.9% to 8.7% over 36 to 40 weeks, depending on the dosing
When will they see results
Gallstone disease was also linked with the long-term use of GLP-1 agonist drugs
For instance, atrasentan, an ERA, reduced kidney outcome risk by 35% but was also associated with a non-significant increase in hospitalization for HF [16]
Brain Journal
